For the Inventor, By the Inventor

Enter assignee name

Berlin, Germany

Epigenomics Ag

USPTO Granted Patents = 68

CIPO Patents = 2

EPO Patents = 51

Trademarks = 3

Forward Citations = 456

Loading Chart...

Loading Chart...

75 inventors (with patents filed for the assignee):

Kurt Berlin (27 out of 27 patents)

Reimo Tetzner (18 out of 19 patents)

Fabian Model (14 out of 14 patents)

4. Catherine E Lofton-Day (12 out of 12 patents)

5. Juergen Distler (12 out of 12 patents)

6. Ralf Lesche (11 out of 12 patents)

7. Andrew Z Sledziewski (10 out of 10 patents)

8. Matthias Schuster (10 out of 12 patents)

9. Alexander Olek (10 out of 12 patents)

10. Matthias Ballhause (9 out of 9 patents)

11. Dimo Dietrich (9 out of 12 patents)

12. Thomas Hildmann (6 out of 7 patents)

13. Xiaoling Song (6 out of 6 patents)

14. Jörn Lewin (4 out of 6 patents)

15. Joern Lewin (4 out of 4 patents)

Core Competencies:

CpG Methylation

Cancer Diagnosis

Nucleic Acids

Cell Proliferative Disorders

Gene Expression Analysis

Breast Cancer Prognosis

Bisulfite Treatment

DNA Methylation Quantification

Colorectal Disorders

DNA Amplification Systems

Cytosine Methylation Detection

Metastasis Detection

68 patents: Sort by Forward Citations

1. 11345966 - Methods for detecting CpG methylation and for diagnosing cancer (2022-05-31),

2. 11261499 - Methods and nucleic acids for determining the prognosis of a cancer subject (2022-03-01),

3. 11186879 - Methods and nucleic acids for analyses of cellular proliferative disorders (2021-11-30),

4. 10731215 - Method for determining the presence or absence of methylation in a sample (2020-08-04),

5. 10626462 - Methods and nucleic acids for determining the prognosis of a cancer subject (2020-04-21),

6. 10385402 - Methods and nucleic acids for analyses of cellular proliferative disorders (2019-08-20),

7. 9988683 - Method and nucleic acids for the analysis of colon cell proliferative disorders (2018-06-05),

8. 9957575 - Methods for detecting CpG methylation and for diagnosing cancer (2018-05-01),

9. 9939441 - Methods and nucleic acids for analyses for cellular proliferative disorders (2018-04-10),

10. 9868756 - Method for bisulfite treatment (2018-01-16),

11. 9863001 - Method for the detection of cytosine methylations in DNA (2018-01-09),

12. 9850532 - Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders (2017-12-26),

13. 9719131 - Method for determining the degree of methylation of defined cytosines in genomic DNA in the sequence context of 5'-CpG-3′ (2017-08-01),

14. 9695478 - Methods and nucleic acids for the analyses of cellular proliferative disorders (2017-07-04),

15. 9670546 - Methods and nucleic acids for analyses of cell proliferative disorders (2017-06-06),

Epigenomics AG is a molecular diagnostics company focused on developing and commercializing innovative products for cancer diagnosis. They specialize in the development and implementation of blood-based tests for early cancer detection, prognosis, and personalized treatment. With a strong focus on epigenetic biomarkers, Epigenomics aims to improve patient outcomes by providing accurate, reliable, and non-invasive diagnostic solutions. For more information, visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

68 Patents

#19 in D-1000 Berlin

#849 in Germany

#10,453 in the World

Berlin, Germany

Epigenomics Ag

Forward Citations = 456

75 inventors:

Kurt Berlin (27 out of 27 patents)

Reimo Tetzner (18 out of 19 patents)

Fabian Model (14 out of 14 patents)

4. Catherine E Lofton-Day (12 out of 12 patents)

5. Juergen Distler (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…